Payment overview · 2025
General Payments
$191.75
11 reported records · 11 companies
Healthcare provider profile · identity verified
Bithika Ray, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MANKATO, MN · NPI 1871725804
Verified facts
What the public records show
CMS Open Payments records show Bithika Ray, M.D. received $191.75 in general payments during 2025 across 11 reported records.
Medtronic, Inc. accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.40 | 12.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.06 | 10.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.34 | 10.1% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.25 | 10.0% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $16.41 | 8.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.27 | 8.5% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.26 | 8.5% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.70 | 8.2% | 1 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.57 | 8.1% | 1 | 2025 |
| Surgenex LLC | Unresolved — no canonical attribution shown | $14.42 | 7.5% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $14.07 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $191.75 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 78 |
| Losartan Potassium | Losartan Potassium | 239 | 70 |
| Omeprazole | Omeprazole | 238 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 60 |
| Metformin Hcl Er | Metformin Hcl | 168 | 54 |
| Lisinopril | Lisinopril | 158 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 32 |
| Gabapentin | Gabapentin | 124 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 39 |
| Potassium Chloride | Potassium Chloride | 109 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 105 | 20 |
| Simvastatin | Simvastatin | 103 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 35 |
| Montelukast Sodium | Montelukast Sodium | 95 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 84 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 26 |
| Trulicity | Dulaglutide | 79 | 14 |
| Furosemide | Furosemide | 78 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 20 |
| Trazodone Hcl | Trazodone Hcl | 71 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 28 |
| Ozempic | Semaglutide | 67 | 16 |
| Alendronate Sodium | Alendronate Sodium | 65 | 25 |
| Eliquis | Apixaban | 64 | 11 |
| Metformin Hcl | Metformin Hcl | 62 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 17 |
| Sertraline Hcl | Sertraline Hcl | 55 | 16 |
| Famotidine | Famotidine | 49 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 18 |
| Jardiance | Empagliflozin | 47 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 15 |
| Estradiol | Estradiol | 44 | 19 |
| Sucralfate | Sucralfate | 43 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 16 |
| Ezetimibe | Ezetimibe | 40 | 12 |
| Clonazepam | Clonazepam | 39 | 13 |
| Warfarin Sodium | Warfarin Sodium | 39 | 14 |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | 12 |
| Hydrocortisone | Hydrocortisone | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Alprazolam | Alprazolam | 33 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 12 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Nystatin | Nystatin | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | 11 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $191.75 · 11 records | Medtronic, Inc. | ArdeoGraft, Cologuard Collection Kit, Dexcom G6 Transmitter, Empaveli, INCEPTIV, OPSUMIT, PYRUKYND, PelloGraft, REZDIFFRA, RenoGraft, SurGraft, SurMatrix, TARPEYO, UPTRAVI, VOQUEZNA, VYKAT XR | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error